Sermorelin is a synthetic GHRH 1–29 analog with a short plasma half-life and a documented 1990s pediatric diagnostic-stimulation trail; CJC-1295 is a longer-acting GHRH analog offered with or without a Drug Affinity Complex (DAC) that extends its half-life by binding serum albumin. Both bind the same GHRH receptor, both have zero human efficacy RCTs for body composition, anti-aging, or sleep, both are WADA-prohibited under S2, and neither is FDA approved.
Both peptides share a critical honest verdict: zero published human RCTs as of August 2026 for the indications most readers are evaluating. Sermorelin's peer-reviewed body of work is anchored in 1990s pediatric GH-deficiency diagnostic-stimulation trials (Sermorelin deep-dive) and one Walker 1994 pharmacodynamic study in healthy adults — it tests acute GH release under controlled diagnostic conditions, not body composition, not anti-aging, not sleep. CJC-1295 has no published navigator trial in the Sermorelin-set citations and is referenced in this comparison only through the broader GHRH-receptor mechanism class and the pharmacodynamic anchor in the Sermorelin deep-dive — there is no peer-reviewed CJC-1295 RCT for body composition, anti-aging, or sleep. This page does not introduce new citations; it maps the existing Sermorelin deep-dive evidence onto the half-life / dosing-frequency distinction that separates Sermorelin from CJC-1295.
Each row states a claim that is supported by a specific peer-reviewed citation where one exists, or by an established pharmacodynamic mechanism class where the mechanism is shared across the class. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).
| Claim | Sermorelin evidence | CJC-1295 evidence |
|---|---|---|
| Receptor target & mechanism class | Strong (mechanistic)GHRH 1–29 synthetic analog. Binds the pituitary GHRH receptor and amplifies endogenous GH pulsatility without replacing it. Receptor pharmacology well characterized. | Strong (mechanistic)Long-acting GHRH analog, offered with or without a Drug Affinity Complex (DAC) that binds serum albumin to extend plasma half-life. Acts at the same GHRH receptor — the change is pharmacokinetic duration, not receptor pharmacology. PMID: 7527273 |
| GH pulsatility in healthy adults (pharmacodynamic baseline) | Established (human pharmacodynamic)Walker 1994 characterized Sermorelin-induced amplification of endogenous GH pulsatility in healthy adults at multiple doses — the same GHRH-receptor pathway CJC-1295 targets. PMID: 7527273 | Mechanism-class onlyCJC-1295 acts at the same GHRH receptor; mechanism-class extension of the same pharmacodynamic finding. No Sermorelin-set citation supports CJC-1295-specific GH-pulse magnitude data in humans. |
| Pediatric GH-deficiency diagnostic stimulation | Established (human)Reutens 1996 characterized the GHRH 1–29 (Sermorelin) diagnostic-stimulation profile in GH-deficient children; established the pediatric GH-deficiency testing window. PMID: 8834260 | Not establishedNo published diagnostic-stimulation history for CJC-1295 in any population. The compound is referenced in the Ipamorelin deep-dive as a GHRH "synergist" but does not appear in the diagnostic-stimulation literature. |
| Half-life / dosing-frequency rationale | Mechanism onlyShort plasma half-life (~10–12 minutes after IV bolus in the diagnostic context) is the limiting pharmacokinetic feature — nightly subcutaneous dosing in community protocols attempts to track the natural nocturnal GH pulse. No new citations introduced. | Mechanism onlyDAC-modified CJC-1295 binds serum albumin to extend half-life (community-reported multi-day window); non-DAC CJC-1295 has a longer half-life than Sermorelin but shorter than the DAC variant. Pharmacokinetics only; no Sermorelin-set citation supports CJC-1295-specific human half-life figures. PMID: 7527273 |
| Endogenous GH-pulse preservation vs replacement | Established (mechanistic)Sermorelin amplifies rather than replaces the natural pulse architecture — preserves endogenous GHRH output. PMID: 7527273 | Pharmacologically plausibleSame receptor — same upstream pulse-amplification class. The longer half-life means the GH pulse profile tracks less closely to the natural nocturnal GH-peak window; community concerns include potential dysregulation of the endogenous pulse architecture. No Sermorelin-set citation supports this claim for CJC-1295 specifically. |
| Sleep architecture / slow-wave recovery | Not establishedNo published sleep-architecture studies for Sermorelin. Mechanistic claim only. | Mechanism onlyGH pulsatility → slow-wave sleep is mechanistic, not RCT-established. CJC-1295's longer half-life means the GH-pulse profile is decoupled from the nocturnal slow-wave window. |
| Body composition / fat loss / muscle gain | NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for Sermorelin. | NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for CJC-1295. |
| Anti-aging / longevity outcomes | NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. Sermorelin withdrawn from US market 2008. | NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. |
| Human randomized controlled trial (any efficacy indication) | NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, or sleep efficacy as of August 2026. | NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, or sleep efficacy as of August 2026. No Sermorelin-set citation supports CJC-1295-specific efficacy RCTs. |
| WADA status | Prohibited (S2 — GH-Releasing Factors subcategory, at all times) | Prohibited (S2 — GH-Releasing Factors subcategory, at all times) |
| FDA status | Not approved. Withdrawn from US market in 2008. No compounding monograph; subject to the July 2026 FDA reclassification review. | Not approved. Has never been FDA approved for any indication. No compounding monograph; subject to the July 2026 FDA reclassification review. |
Citations reused from the Sermorelin deep-dive — PMIDs are limited to the set already cited in the underlying deep-dive (PubMed identifiers 8834260, 7527273) — no new citations introduced. CJC-1295 statements are restricted to the mechanism class and regulatory context already documented across the Sermorelin and Ipamorelin deep-dives.
Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.
Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the mechanistic rationale is strongest.
Sermorelin is the only candidate in this comparison with a 1990s pediatric diagnostic-stimulation trail and a 1994 pharmacodynamic anchor in healthy adults (PMID: 7527273; PMID: 8834260) — the binding at the GHRH receptor and the amplification of the natural pituitary pulse architecture characterize Sermorelin's most-cited mechanistic appeal. The short half-life is treated as the feature that keeps the GH-pulse profile closely aligned to the natural nocturnal window. Caveats: Sermorelin was withdrawn from the US market in 2008; it is not approved and is subject to the July 2026 FDA reclassification review; zero published human RCTs using body-composition, anti-aging, or sleep endpoints; half-life does not establish efficacy.
CJC-1295's distinguishing feature is pharmacokinetic, not pharmacodynamic: the DAC modification (or the non-DAC longer-half-life variant) extends the GHRH-receptor occupancy profile beyond Sermorelin's short window — hence the weekly community-reported schedule. Same receptor, different duration. Caveats: zero published peer-reviewed human RCTs for any indication; the longer half-life decouples the GH-elevation profile from the natural nocturnal pulse window (a pharmacodynamic concern); CJC-1295 has never been FDA approved for any indication; both peptides are WADA S2-prohibited. Half-life is not a substitute for efficacy.
Combining Sermorelin and CJC-1295 is common in community GH-axis stacks because the two peptides share a receptor but differ in half-life — Sermorelin nightly for transient amplification, CJC-1295 weekly for sustained background occupancy (PMID: 7527273). The rationale is pharmacokinetic complementarity at the same receptor step, not receptor-mechanism diversity. Caveats: same-receptor overlap means any GH-axis biology that follows GHRH-receptor activation is amplified, not diversified — safety and efficacy on the pair is unestablished; both peptides are WADA S2-prohibited (positive test on either remains a positive test); Sermorelin was withdrawn from the US market in 2008 and CJC-1295 has never been approved — subject to the July 2026 FDA reclassification review.
"Evidence tier" is the most important field in every claim above. Two peptides can share a use case while having radically different evidence behind that use case. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (WADA S2): Sermorelin and CJC-1295 are both prohibited at all times under WADA S2 (GH-Releasing Factors subcategory — also covering GHRPs and Tesamorelin). A positive test for either results in a ban, and there is no Therapeutic Use Exemption (TUE) pathway for either compound. The WADA categorization is legally identical between Sermorelin and CJC-1295.
Anyone seeking an FDA-approved therapy: neither peptide is approved for any human indication. Sermorelin was withdrawn from the US market in 2008 (commercial reasons, not safety). CJC-1295 has never been FDA approved. Both peptides have no compounding monograph and sit in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones. Stacking amplifies regulatory exposure without adding evidence.
Anyone needing proven human efficacy: zero published human RCTs for both peptides for adult body composition, anti-aging, or sleep efficacy as of August 2026. Community-reported outcomes are not clinical evidence. Half-life is not efficacy: choosing CJC-1295 over Sermorelin to minimize injection frequency does not establish clinical benefit. If you need a therapy with validated human efficacy, neither peptide is the right starting point — much less the combination.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.